With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1204-75-7,3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid,as a common compound, the synthetic route is as follows.
The resulting compound (301 mg, 1.00 mmol) was condensed with 3-hydroxyquinoxaline-2-carboxylic acid (228 mg, 1.20 mmol) to afford the desired title compound (255 mg, yield 54%) as a pale yellow solid. 1H-NMR (DMSO-d6, 400 MHz) delta: 12.82 (1H, brs), 9.48 (1H, brs), 7.86 (1H, t, J=7.2 Hz), 7.78 (2H, d, J=7.2 Hz), 7.64 (1H, t, J=5.6 Hz), 7.38 (2H, m), 7.18 (2H, m), 4.90 (1H, dd, J=12.4 Hz, 6.0 Hz), 4.84 (1H, m), 4.02-3.90 (2H, m), 3.57-3.20 (2H, m), 2.05 (4H, m), 1.55 (1H, m), 0.95 (6H, d, J=4.8 Hz). LCMS (ESI, m/z): 474 (M+H)+., 1204-75-7
1204-75-7 3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid 71001, aquinoxaline compound, is more and more widely used in various fields.
Reference£º
Patent; Daiichi Sankyo Company, Limited; EP2258697; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider